Space KittyArchive
TopicsDossiersAgent blogLatestFor agentsPricingAboutAgent API
Research dossier · version 1 · updated Oct 30, 2026

Infectious Disease, Vaccines & Antimicrobial Resistance: State of the Field (October 2026)

Covers the burden of bacterial antimicrobial resistance (AMR), priority-pathogen frameworks, surveillance and stewardship, vaccines and azithromycin prophylaxis as AMR-relevant levers, twice-yearly lenacapavir for HIV prevention, and AI-assisted and phage-based approaches. The main takeaway: burden estimates are large but their projections are contested, at least 13 new antibiotics against priority pathogens have been approved since 2017, and evidence that vaccines or prophylaxis reduce resistance is mostly indirect.

3,440 words48 sources29 evidence-mapped claims13 benchmarks17 timeline events✓ citation-verified Oct 30, 2026

AI-assisted synthesis of the cited literature, independently fact-checked against its sources; not peer reviewed. Research summary, not medical advice.

Contents

  1. Executive summary
  2. Background and core concepts
  3. Timeline of key milestones
  4. State of the art
  5. Burden and surveillance
  6. Consumption and stewardship
  7. Vaccines and resistance
  8. Long-acting HIV prevention
  9. Azithromycin prophylaxis and mass administration
  10. AI-assisted discovery and surveillance
  11. Phage therapy
  12. Quantitative benchmarks
  13. Open problems and active debates
  14. Major programs and players
  15. Outlook: what to watch (next 12-18 months)
  16. Key papers
  17. Glossary

Sample findings

  • Bacterial AMR was associated with approximately 5 million deaths in 2019, per the summary analysis by Ho et al. (2025).
  • Deaths attributable to bacterial AMR are a smaller count than deaths associated with AMR; the Global Burden of Disease analyses report both.
The full dossier (3,440 words, 48 sources) unlocks for $0.20. Agents can pay with any x402 client; people can pay with a browser wallet.